

# Bernhard Hellmich

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6230501/publications.pdf>

Version: 2024-02-01

42  
papers

6,966  
citations

218677

26  
h-index

155660

55  
g-index

66  
all docs

66  
docs citations

66  
times ranked

4608  
citing authors

#	ARTICLE	IF	CITATIONS
1	Utility of serum complement factors C3 and C4 as biomarkers during therapeutic management of giant cell arteritis. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 276-282.	1.1	2
2	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	5.6	78
3	Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature. <i>Autoimmunity Reviews</i> , 2022, 21, 103034.	5.8	8
4	Response to: "Error in the dosage of methotrexate in the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis"™ by Scheicht. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e90-e90.	0.9	0
5	Efficacy and safety of mavrimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 653-661.	0.9	49
6	Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Rheumatology</i> , 2021, 60, 4355-4360.	1.9	21
7	Evaluation of PR3- and MPO-ANCA line and dot immunoassays in ANCA-associated vasculitis. <i>Rheumatology</i> , 2021, 60, 4390-4394.	1.9	2
8	New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a claims data study. <i>Rheumatology</i> , 2021, 60, 4868-4873.	1.9	23
9	AB0370...UTILITY OF CRP AND ESR IN THE DIAGNOSIS OF GIANT CELL ARTERITIS RELAPSE IN A PHASE 2 TRIAL OF MAVRILIMUMAB. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1211-1212.	0.9	1
10	GCA management guidelines "vive la différence". <i>Nature Reviews Rheumatology</i> , 2021, 17, 649-650.	8.0	4
11	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 19-30.	0.9	667
12	Treatment of Giant Cell Arteritis and Takayasu Arteritis"Current and Future. <i>Current Rheumatology Reports</i> , 2020, 22, 84.	4.7	19
13	Usefulness of vasculitis biomarkers in the era of the personalized medicine. <i>Autoimmunity Reviews</i> , 2020, 19, 102514.	5.8	13
14	International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1360-1372.	5.6	36
15	Two Immunocompromised Patients With Diffuse Alveolar Hemorrhage as a Complication of Severe Coronavirus Disease 2019. <i>Chest</i> , 2020, 158, e215-e219.	0.8	12
16	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 952-963.	5.6	82
17	027. ANCA STATUS IN EOSINOPHIL GRANULOMATOSIS WITH POLYANGIITIS: A MONOCENTRIC COHORT ANALYSIS OF MANIFESTATIONS AND RELAPSES OF ANCA-POSITIVE AND ANCA-NEGATIVE PATIENTS. <i>Rheumatology</i> , 2019, 58, .	1.9	2
18	FRI0284...RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS: EVIDENCE TO GUIDE THE MANAGEMENT OF GIANT CELL ARTERITIS. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
19	THU0286â€¦MANAGEMENT OF TAKAYASU ARTERITIS: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS. , 2019, , .		2
20	Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open, 2019, 5, e001003.	3.8	52
21	Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. RMD Open, 2019, 5, e001020.	3.8	56
22	Anti-neutrophil cytoplasm antibodies (ANCA): Recent methodological advancesâ€”Lead to new consensus recommendations for ANCA detection. Journal of Immunological Methods, 2018, 456, 1-6.	1.4	10
23	Individual values of antineutrophil cytoplasmic antibodies do not correspond between antigen-specific assays. Clinical Chemistry and Laboratory Medicine, 2018, 56, e39-e42.	2.3	12
24	Revised 2017 international consensus on testing of ANCA in granulomatosis with polyangiitis and microscopic polyangiitis. Nature Reviews Rheumatology, 2017, 13, 683-692.	8.0	302
25	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. RMD Open, 2017, 3, e000449.	3.8	23
26	EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2016, 75, 1583-1594.	0.9	940
27	Evaluation of automated multi-parametric indirect immunofluorescence assays to detect anti-neutrophil cytoplasmic antibodies (ANCA) in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Autoimmunity Reviews, 2016, 15, 736-741.	5.8	56
28	A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churgâ€”Strauss, EGPA): monocentric experiences in 150 patients. Annals of the Rheumatic Diseases, 2013, 72, 1011-1017.	0.9	226
29	Targeting Interleukin-5 in Refractory and Relapsing Churgâ€”Strauss Syndrome. Annals of Internal Medicine, 2011, 155, 341.	3.9	180
30	Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study. Clinical and Experimental Rheumatology, 2010, 28, 24-30.	0.8	34
31	EULAR recommendations for the management of primary small and medium vessel vasculitis. Annals of the Rheumatic Diseases, 2009, 68, 310-317.	0.9	889
32	EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases, 2009, 68, 318-323.	0.9	596
33	Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Annals of the Rheumatic Diseases, 2008, 67, 1004-1010.	0.9	343
34	A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clinical and Experimental Rheumatology, 2008, 26, S35-40.	0.8	13
35	Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology, 2007, 46, 1087-1091.	1.9	196
36	EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Annals of the Rheumatic Diseases, 2007, 66, 605-617.	0.9	524

#	ARTICLE	IF	CITATIONS
37	Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 222-227.	0.9	1,041
38	Proinflammatory Cytokines and Autoimmunity in Churg-Strauss Syndrome. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 121-131.	3.8	118
39	Intravenous Immunoglobulin Therapy in Vasculitis: Speculation or Evidence?. <i>Clinical Reviews in Allergy and Immunology</i> , 2005, 29, 237-246.	6.5	41
40	Recent progress in the pharmacotherapy of Churg-Strauss syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 25-35.	1.8	45
41	Churg Strauss syndrome--successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. <i>Clinical and Experimental Rheumatology</i> , 2004, 22, S52-61.	0.8	45
42	Update on the pathogenesis of Churg-Strauss syndrome. <i>Clinical and Experimental Rheumatology</i> , 2003, 21, S69-77.	0.8	43